{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023598","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.406126+00:00","generated_at":"2026-05-17T14:00:02.058030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%","bullets":["Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.","Adjusted EBITDA negative $5.1M vs negative $4.7M; cash $7.2M at June 30.","Acquired US IP and NDA from Biofrontera AG; new Ameluz royalty 12%/15% vs prior 25-35%.","Received $11M additional funding; US patent for revised Ameluz granted through 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023598","json":"https://secwatch.observer/filing/0001641172-25-023598.json","markdown":"https://secwatch.observer/filing/0001641172-25-023598.md","text":"https://secwatch.observer/filing/0001641172-25-023598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/0001641172-25-023598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:00:02.058030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}